glp-1 hashimoto New Hashimoto’s Treatment in 2025 Tirzepatide for Hashimoto's Disease: Evidence

While the FDA first approved GLP-1s in 2005, 6% of Americans are now on medications like Ozempic, Wegovy, Mounjaro, and Zepbound, and 12% of US adults have tried a GLP-1and that number keeps climbing

When we look at the research, the numbers are reassuring

But, they might look like melena to someone who doesnt know better

doi:10.1007/s13300-011-0002-3 Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W

Researchers studying oral peptide bioavailability should reference the specific published literature on GHK-Cu oral research

Most of them were not on nephroprotective drugs such as SGLT-2 inhibitors (75%) and mineralocorticoid receptor antagonists (92%), while 81% of patients were on ACE-I or ARBs [49]